Macular Degeneration (AMD) and Other Retinal Diseases Market Size, Share & Growth Report 2032
Macular Degeneration (AMD) and Other Retinal Diseases Market Size, Share & Growth Report 2032
Segments - by Disease Type (Wet AMD, Dry AMD, Diabetic Retinopathy, Retinal Vein Occlusion, Diabetic Macular Edema, Others), by Treatment Type (Surgical Treatments, Intraocular Implants, Pharmacological Treatments), by Drug Class (Anti-VEGF Agents, Retinoids, Corticosteroids, Gene Therapy), by End-user (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, Others)
Upcoming
| Report ID :HC-7347
| 4.5 Rating
| 74 Reviews
| 267 Pages
| Format :
Report Description
Macular Degeneration (AMD) and Other Retinal Diseases Market Outlook 2032
The global macular degeneration (AMD) and other retinal diseases market size was USD 8.9 billion in 2023 and is likely to reach USD 15.4 billion by 2032, expanding at a CAGR of 6.5% during 2024–2032. The market growth is attributed to home-based retinal monitoring and patient-centered care.
Age-related macular degeneration (AMD) and other retinal diseases are a group of vision-impairing conditions that affect the retina the light-sensitive tissue at the back of the eye. AMD primarily impacts the macula, which is responsible for central vision and fine detail, and it is categorized into wet (neovascular) and dry (atrophic). Other significant retinal diseases include diabetic retinopathy, retinal vein occlusion, and diabetic macular edema, all of which lead to progressive vision loss if untreated. These conditions are often linked to aging, diabetes, or vascular problems and require specialized medical management.
Home-based retinal monitoring is gaining traction as a key trend in the AMD and other retinal diseases market, especially with the rise of portable, easy-to-use devices for retinal imaging and monitoring. These devices enable patients to track their condition from the comfort of their homes, reducing the need for frequent in-person visits and enhancing treatment adherence. Additionally, the trend toward patient-centered care is reshaping how retinal diseases are managed. By focusing on personalized care plans, patient preferences, and improved communication between patients and healthcare providers, there is a greater emphasis on improving quality of life and outcomes. These trends are expected to drive efficient and accessible care, particularly for those with chronic or age-related retinal conditions.
Macular Degeneration (AMD) and Other Retinal Diseases Market Dynamics
Major Drivers
The global rise in the aging population is one of the primary drivers of the AMD and other retinal diseases market, as these conditions are strongly age-related. As life expectancy increases worldwide, especially in developed and emerging economies, the number of individuals over the age of 60 continues to grow heightening the prevalence of age-related vision disorders such as macular degeneration. Older adults are susceptible to degenerative changes in the retina, leading to an expanding patient pool in need of ongoing ophthalmic care and therapeutic interventions.
Rapid innovations in retinal treatment technologies have significantly boosted market growth. Breakthroughs such as anti-VEGF injections, sustained-release intraocular implants, laser-based therapies, and emerging gene and cell therapies are transforming patient outcomes and clinical practices. These advancements allow for earlier detection, more effective disease management, and less frequent dosing, which improves patient compliance. Demand for novel and personalized treatment solutions continues to rise, attracting investment and driving competition among biotech and pharmaceutical companies.
The increasing global incidence of retinal diseases driven by factors such as diabetes, hypertension, and unhealthy lifestyles is contributing to the growing demand for retinal disease management. Diabetic retinopathy and diabetic macular edema, in particular, are on the rise due to the global diabetes epidemic. In addition, retinal vein occlusion and age-related macular degeneration are becoming common, leading to a surge in diagnosis rates and a greater need for long-term treatment. This rising burden has heightened awareness among healthcare providers and patients, further propelling market expansion.
Existing Restraints
The high cost associated with the diagnosis, treatment, and ongoing management of retinal diseases is a major barrier to wider market adoption, especially in lower-income populations. Anti-VEGF therapies, which are the standard of care for conditions such as wet AMD and diabetic macular edema, require frequent intravitreal injections often monthly leading to substantial cumulative expenses. Additionally, advanced surgical procedures and imaging diagnostics such as optical coherence tomography (OCT) add to the financial burden. For many patients, especially those without comprehensive insurance coverage, the cost is prohibitive, limiting treatment adherence and overall outcomes.
Limited access to quality eye care and advanced retinal treatments remains significantly limited in many developing and under-resourced regions. Factors such as inadequate healthcare infrastructure, shortage of trained ophthalmologists, and lack of awareness about retinal diseases contribute to delayed diagnosis and undertreatment. In rural areas, even basic screening services are unavailable, and logistical challenges further hinder regular follow-up care. This disparity in access prevents a large segment of the global population from benefiting from the latest therapeutic advancements, thereby restraining overall market growth in these regions.
Emerging Opportunities
Expansion in emerging markets such as India, China, Brazil, and parts of Southeast Asia and Africa offers significant growth potential due to improving healthcare infrastructure, rising disposable incomes, and growing awareness about eye health. As these countries invest in healthcare systems and universal insurance schemes, access to diagnostic services and advanced treatments is expected to increase. Furthermore, the large and aging populations in these regions create a vast, underserved patient base. Pharmaceutical companies are recognizing this opportunity and expanding their footprint through localized manufacturing, strategic partnerships, and affordable treatment models tailored to regional needs.
The development of gene and cell therapies presents a transformative opportunity in the treatment of retinal diseases, particularly for conditions such as inherited retinal dystrophies and advanced AMD that currently have limited or no cure. These therapies aim to address the root causes of disease at the genetic level or regenerate damaged retinal tissue, offering the possibility of long-term or permanent vision restoration. Recent FDA approvals and promising clinical trial results are accelerating interest and investment in this space. As research progresses and regulatory pathways become clearer, gene and cell therapies are expected to become a major growth driver in the coming decade.
Scope of the Macular Degeneration (AMD) and Other Retinal Diseases Market Report
The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics have also been included in the report.
|
Attributes |
Details |
|
Report Title |
Macular Degeneration (AMD) and Other Retinal Diseases Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
|
Base Year |
2023 |
|
Historic Data |
2017 -2022 |
|
Forecast Period |
2024–2032 |
|
Segmentation |
Disease Type (Wet AMD, Dry AMD, Diabetic Retinopathy, Retinal Vein Occlusion, Diabetic Macular Edema, and Others), Treatment Type (Surgical Treatments, Intraocular Implants, and Pharmacological Treatments), Drug Class (Anti-VEGF Agents, Retinoids, Corticosteroids, and Gene Therapy), and End-user (Hospitals, Specialty Clinics, Ambulatory Surgical Centers, and Others) |
|
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
|
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast |
|
Key Players Covered in the Report |
Regeneron Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Bayer AG, Pfizer Inc., Bausch Health Companies Inc., Apellis Pharmaceuticals, Santen Pharmaceutical Co., Ltd., Adverum Biotechnologies, Inc., and Allergan (AbbVie Inc.) |
Regional Outlook
North America holds the largest share of the AMD and other retinal diseases market, with the US being the dominant contributor. The prevalence of age-related macular degeneration (AMD) and other retinal diseases is notably high in this region due to the aging population. The US benefits from advanced healthcare infrastructure, widespread access to specialized ophthalmologists, and a strong focus on research and development, particularly in the areas of gene therapies and advanced biologics. Canada plays a significant role, with increasing awareness, government healthcare programs, and growing investments in ophthalmology innovations. Regulatory bodies such as the FDA have approved several novel treatments, including anti-VEGF therapies, which have further driven the market growth in this region.
Europe is a prominent region for the AMD and other retinal diseases market, led by Germany, the UK, and France. The aging population across European countries contributes to the rising demand for AMD treatments. Germany is one of the leading countries, with a strong healthcare system and high spending on retinal care. The UK and France exhibit substantial market growth due to their robust healthcare systems, ongoing clinical trials, and the availability of advanced treatments. European healthcare policy and reimbursement structures significantly influence the market, with increasing adoption of novel therapies and improved access to treatment in many countries. Thus, in turn, is expected to boost the market in the region.
Asia Pacific is expected to witness substantial growth in the AMD and other retinal diseases market in the coming years. Japan holds a significant share of the market, driven by its aging population and well-established healthcare system that supports the adoption of advanced treatments. China and India represent high-growth opportunities due to their large populations and rising prevalence of retinal conditions. These markets are witnessing significant investments in healthcare infrastructure, including the expansion of specialized eye care centers. The increasing economic power of these nations, combined with government healthcare initiatives, is driving the adoption of innovative treatments such as anti-VEGF agents. APAC, including countries such as South Korea and Australia, contributes to the region's growth due to improving healthcare access and a growing focus on retinal disease management.
Macular Degeneration (AMD) and Other Retinal Diseases Market Segment Insights
Disease Type Segment Insights
Wet AMD is the dominant segment within the AMD and other retinal diseases market. This condition involves the growth of abnormal blood vessels beneath the retina, leading to rapid vision loss. The high prevalence of wet AMD among the aging population, coupled with its severe impact on vision, has driven significant demand for effective treatments. Therapeutic options such as anti-VEGF (vascular endothelial growth factor) therapies have been central to managing this condition. The continuous need for frequent injections and the associated healthcare costs have contributed to wet AMD's substantial market share.
Dry AMD is anticipated to experience the highest growth rate in the coming years. This form of AMD is characterized by the gradual breakdown of retinal cells, leading to vision impairment. The increasing global elderly population is a significant factor driving the rise in dry AMD cases. Recent advancements in research and development, along with the introduction of new therapies, are expected to enhance treatment outcomes and patient quality of life, thereby expanding the market share of dry AMD.
Treatment Type Segment Insights
Pharmacological treatments dominated the AMD and other retinal diseases market, due to the widespread use of anti-VEGF (vascular endothelial growth factor) therapies such as Eylea (aflibercept), Lucentis (ranibizumab), and Beovu (brolucizumab). These injectable medications are considered the standard of care for conditions such as wet AMD, diabetic macular edema, and retinal vein occlusion. Their effectiveness in reducing retinal fluid accumulation and preserving vision has led to their extensive adoption across healthcare settings. However, challenges such as the high cost of branded drugs and the growing availability of biosimilars are influencing market dynamics.
Intraocular implants are anticipated to experience significant growth in the coming years. These implants offer sustained drug delivery, reducing the frequency of injections required for conditions such as wet AMD and diabetic macular edema. The development of innovative implants that provide long-term therapeutic effects is expected to enhance patient compliance and treatment outcomes, thereby driving the segment's expansion.
Drug Class Segment Insights
Anti-VEGF (vascular endothelial growth factor) agents dominated the AMD and other retinal diseases market. This dominance is attributed to the high efficacy of anti-VEGF therapies in treating conditions such as wet AMD, diabetic macular edema, and retinal vein occlusion. Medications such as aflibercept (Eylea), ranibizumab (Lucentis), and brolucizumab (Beovu) have become standard treatments due to their ability to inhibit abnormal blood vessel growth and leakage in the retina. The widespread adoption of these therapies has significantly contributed to their market leadership.
Gene therapy is projected to witness substantial growth during the forecast period. This innovative approach aims to provide long-term solutions by delivering genes that produce therapeutic proteins directly within the eye, reducing the need for frequent injections. Advancements in gene delivery technologies and promising clinical trial results are driving interest in this segment. The development of gene therapies targeting retinal diseases holds the potential to revolutionize treatment paradigms, offering sustained efficacy and improved patient compliance.
End-user Segment Insights
Hospitals held the largest share of the AMD and other retinal diseases market. This dominance is attributed to the comprehensive care hospitals provide, including advanced diagnostic tools, specialized ophthalmologists, and the ability to administer complex treatments such as intravitreal injections for wet AMD. The high prevalence of age-related macular degeneration (AMD) among the elderly population and the increasing number of hospital admissions for retinal conditions have further solidified hospitals' leading position in the market.
Specialty clinics are projected to experience significant growth in the coming years. These clinics offer focused expertise in retinal diseases, providing patients with personalized care and specialized treatments. The increasing demand for specialized services, coupled with advancements in diagnostic and therapeutic technologies, is driving the expansion of specialty clinics. Additionally, the convenience and accessibility of these clinics are attracting a growing patient base seeking targeted care for retinal conditions.
Segments
The macular degeneration (AMD) and other retinal diseases market has been segmented on the basis of
Disease Type
- Wet AMD
- Dry AMD
- Diabetic Retinopathy
- Retinal Vein Occlusion
- Diabetic Macular Edema
- Others
Treatment Type
- Surgical Treatments
- Intraocular Implants
- Pharmacological Treatments
Drug Class
- Anti-VEGF Agents
- Retinoids
- Corticosteroids
- Gene Therapy
End-user
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Others
Region
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
Key Players
- Regeneron Pharmaceuticals Inc.
- F. Hoffmann-La Roche Ltd
- Novartis AG
- Bayer AG
- Pfizer Inc.
- Bausch Health Companies Inc.
- Apellis Pharmaceuticals,
- Santen Pharmaceutical Co., Ltd.
- Adverum Biotechnologies, Inc.
- Allergan (AbbVie Inc.)
Competitive Landscape
Key players competing in the global macular degeneration (AMD) and other retinal diseases market are Regeneron Pharmaceuticals Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Bayer AG, Pfizer Inc., Bausch Health Companies Inc., Apellis Pharmaceuticals, Santen Pharmaceutical Co., Ltd., Adverum Biotechnologies, Inc., and Allergan (AbbVie Inc.)
These companies use development strategies including mergers, acquisitions, partnerships, collaboration, and product launches to expand their consumer base worldwide.
Table Of Content
Chapter 1 Executive SummaryChapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Macular Degeneration (AMD) and Other Retinal Diseases Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Macular Degeneration (AMD) and Other Retinal Diseases Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Macular Degeneration (AMD) and Other Retinal Diseases Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Macular Degeneration (AMD) and Other Retinal Diseases Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Size & Forecast, 2023-2032
4.5.1 Macular Degeneration (AMD) and Other Retinal Diseases Market Size and Y-o-Y Growth
4.5.2 Macular Degeneration (AMD) and Other Retinal Diseases Market Absolute $ Opportunity
Chapter 5 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Analysis and Forecast By Disease Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities By Disease Type
5.1.2 Basis Point Share (BPS) Analysis By Disease Type
5.1.3 Absolute $ Opportunity Assessment By Disease Type
5.2 Macular Degeneration (AMD) and Other Retinal Diseases Market Size Forecast By Disease Type
5.2.1 Wet AMD
5.2.2 Dry AMD
5.2.3 Diabetic Retinopathy
5.2.4 Retinal Vein Occlusion
5.2.5 Diabetic Macular Edema
5.2.6 Others
5.3 Market Attractiveness Analysis By Disease Type
Chapter 6 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Analysis and Forecast By Treatment Type
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities By Treatment Type
6.1.2 Basis Point Share (BPS) Analysis By Treatment Type
6.1.3 Absolute $ Opportunity Assessment By Treatment Type
6.2 Macular Degeneration (AMD) and Other Retinal Diseases Market Size Forecast By Treatment Type
6.2.1 Surgical Treatments
6.2.2 Intraocular Implants
6.2.3 Pharmacological Treatments
6.3 Market Attractiveness Analysis By Treatment Type
Chapter 7 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Analysis and Forecast By Drug Class
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities By Drug Class
7.1.2 Basis Point Share (BPS) Analysis By Drug Class
7.1.3 Absolute $ Opportunity Assessment By Drug Class
7.2 Macular Degeneration (AMD) and Other Retinal Diseases Market Size Forecast By Drug Class
7.2.1 Anti-VEGF Agents
7.2.2 Retinoids
7.2.3 Corticosteroids
7.2.4 Gene Therapy
7.3 Market Attractiveness Analysis By Drug Class
Chapter 8 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Analysis and Forecast By End-user
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities By End-user
8.1.2 Basis Point Share (BPS) Analysis By End-user
8.1.3 Absolute $ Opportunity Assessment By End-user
8.2 Macular Degeneration (AMD) and Other Retinal Diseases Market Size Forecast By End-user
8.2.1 Hospitals
8.2.2 Specialty Clinics
8.2.3 Ambulatory Surgical Centers
8.2.4 Others
8.3 Market Attractiveness Analysis By End-user
Chapter 9 Global Macular Degeneration (AMD) and Other Retinal Diseases Market Analysis and Forecast by Region
9.1 Introduction
9.1.1 Key Market Trends & Growth Opportunities By Region
9.1.2 Basis Point Share (BPS) Analysis By Region
9.1.3 Absolute $ Opportunity Assessment By Region
9.2 Macular Degeneration (AMD) and Other Retinal Diseases Market Size Forecast By Region
9.2.1 North America
9.2.2 Europe
9.2.3 Asia Pacific
9.2.4 Latin America
9.2.5 Middle East & Africa (MEA)
9.3 Market Attractiveness Analysis By Region
Chapter 10 Coronavirus Disease (COVID-19) Impact
10.1 Introduction
10.2 Current & Future Impact Analysis
10.3 Economic Impact Analysis
10.4 Government Policies
10.5 Investment Scenario
Chapter 11 North America Macular Degeneration (AMD) and Other Retinal Diseases Analysis and Forecast
11.1 Introduction
11.2 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size Forecast by Country
11.2.1 U.S.
11.2.2 Canada
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size Forecast By Disease Type
11.6.1 Wet AMD
11.6.2 Dry AMD
11.6.3 Diabetic Retinopathy
11.6.4 Retinal Vein Occlusion
11.6.5 Diabetic Macular Edema
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis By Disease Type
11.8 Absolute $ Opportunity Assessment By Disease Type
11.9 Market Attractiveness Analysis By Disease Type
11.10 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size Forecast By Treatment Type
11.10.1 Surgical Treatments
11.10.2 Intraocular Implants
11.10.3 Pharmacological Treatments
11.11 Basis Point Share (BPS) Analysis By Treatment Type
11.12 Absolute $ Opportunity Assessment By Treatment Type
11.13 Market Attractiveness Analysis By Treatment Type
11.14 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size Forecast By Drug Class
11.14.1 Anti-VEGF Agents
11.14.2 Retinoids
11.14.3 Corticosteroids
11.14.4 Gene Therapy
11.15 Basis Point Share (BPS) Analysis By Drug Class
11.16 Absolute $ Opportunity Assessment By Drug Class
11.17 Market Attractiveness Analysis By Drug Class
11.18 North America Macular Degeneration (AMD) and Other Retinal Diseases Market Size Forecast By End-user
11.18.1 Hospitals
11.18.2 Specialty Clinics
11.18.3 Ambulatory Surgical Centers
11.18.4 Others
11.19 Basis Point Share (BPS) Analysis By End-user
11.20 Absolute $ Opportunity Assessment By End-user
11.21 Market Attractiveness Analysis By End-user
Chapter 12 Europe Macular Degeneration (AMD) and Other Retinal Diseases Analysis and Forecast
12.1 Introduction
12.2 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size Forecast by Country
12.2.1 Germany
12.2.2 France
12.2.3 Italy
12.2.4 U.K.
12.2.5 Spain
12.2.6 Russia
12.2.7 Rest of Europe
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size Forecast By Disease Type
12.6.1 Wet AMD
12.6.2 Dry AMD
12.6.3 Diabetic Retinopathy
12.6.4 Retinal Vein Occlusion
12.6.5 Diabetic Macular Edema
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis By Disease Type
12.8 Absolute $ Opportunity Assessment By Disease Type
12.9 Market Attractiveness Analysis By Disease Type
12.10 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size Forecast By Treatment Type
12.10.1 Surgical Treatments
12.10.2 Intraocular Implants
12.10.3 Pharmacological Treatments
12.11 Basis Point Share (BPS) Analysis By Treatment Type
12.12 Absolute $ Opportunity Assessment By Treatment Type
12.13 Market Attractiveness Analysis By Treatment Type
12.14 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size Forecast By Drug Class
12.14.1 Anti-VEGF Agents
12.14.2 Retinoids
12.14.3 Corticosteroids
12.14.4 Gene Therapy
12.15 Basis Point Share (BPS) Analysis By Drug Class
12.16 Absolute $ Opportunity Assessment By Drug Class
12.17 Market Attractiveness Analysis By Drug Class
12.18 Europe Macular Degeneration (AMD) and Other Retinal Diseases Market Size Forecast By End-user
12.18.1 Hospitals
12.18.2 Specialty Clinics
12.18.3 Ambulatory Surgical Centers
12.18.4 Others
12.19 Basis Point Share (BPS) Analysis By End-user
12.20 Absolute $ Opportunity Assessment By End-user
12.21 Market Attractiveness Analysis By End-user
Chapter 13 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Analysis and Forecast
13.1 Introduction
13.2 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size Forecast by Country
13.2.1 China
13.2.2 Japan
13.2.3 South Korea
13.2.4 India
13.2.5 Australia
13.2.6 South East Asia (SEA)
13.2.7 Rest of Asia Pacific (APAC)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size Forecast By Disease Type
13.6.1 Wet AMD
13.6.2 Dry AMD
13.6.3 Diabetic Retinopathy
13.6.4 Retinal Vein Occlusion
13.6.5 Diabetic Macular Edema
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis By Disease Type
13.8 Absolute $ Opportunity Assessment By Disease Type
13.9 Market Attractiveness Analysis By Disease Type
13.10 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size Forecast By Treatment Type
13.10.1 Surgical Treatments
13.10.2 Intraocular Implants
13.10.3 Pharmacological Treatments
13.11 Basis Point Share (BPS) Analysis By Treatment Type
13.12 Absolute $ Opportunity Assessment By Treatment Type
13.13 Market Attractiveness Analysis By Treatment Type
13.14 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size Forecast By Drug Class
13.14.1 Anti-VEGF Agents
13.14.2 Retinoids
13.14.3 Corticosteroids
13.14.4 Gene Therapy
13.15 Basis Point Share (BPS) Analysis By Drug Class
13.16 Absolute $ Opportunity Assessment By Drug Class
13.17 Market Attractiveness Analysis By Drug Class
13.18 Asia Pacific Macular Degeneration (AMD) and Other Retinal Diseases Market Size Forecast By End-user
13.18.1 Hospitals
13.18.2 Specialty Clinics
13.18.3 Ambulatory Surgical Centers
13.18.4 Others
13.19 Basis Point Share (BPS) Analysis By End-user
13.20 Absolute $ Opportunity Assessment By End-user
13.21 Market Attractiveness Analysis By End-user
Chapter 14 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Analysis and Forecast
14.1 Introduction
14.2 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size Forecast by Country
14.2.1 Brazil
14.2.2 Mexico
14.2.3 Rest of Latin America (LATAM)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size Forecast By Disease Type
14.6.1 Wet AMD
14.6.2 Dry AMD
14.6.3 Diabetic Retinopathy
14.6.4 Retinal Vein Occlusion
14.6.5 Diabetic Macular Edema
14.6.6 Others
14.7 Basis Point Share (BPS) Analysis By Disease Type
14.8 Absolute $ Opportunity Assessment By Disease Type
14.9 Market Attractiveness Analysis By Disease Type
14.10 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size Forecast By Treatment Type
14.10.1 Surgical Treatments
14.10.2 Intraocular Implants
14.10.3 Pharmacological Treatments
14.11 Basis Point Share (BPS) Analysis By Treatment Type
14.12 Absolute $ Opportunity Assessment By Treatment Type
14.13 Market Attractiveness Analysis By Treatment Type
14.14 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size Forecast By Drug Class
14.14.1 Anti-VEGF Agents
14.14.2 Retinoids
14.14.3 Corticosteroids
14.14.4 Gene Therapy
14.15 Basis Point Share (BPS) Analysis By Drug Class
14.16 Absolute $ Opportunity Assessment By Drug Class
14.17 Market Attractiveness Analysis By Drug Class
14.18 Latin America Macular Degeneration (AMD) and Other Retinal Diseases Market Size Forecast By End-user
14.18.1 Hospitals
14.18.2 Specialty Clinics
14.18.3 Ambulatory Surgical Centers
14.18.4 Others
14.19 Basis Point Share (BPS) Analysis By End-user
14.20 Absolute $ Opportunity Assessment By End-user
14.21 Market Attractiveness Analysis By End-user
Chapter 15 Middle East & Africa (MEA) Macular Degeneration (AMD) and Other Retinal Diseases Analysis and Forecast
15.1 Introduction
15.2 Middle East & Africa (MEA) Macular Degeneration (AMD) and Other Retinal Diseases Market Size Forecast by Country
15.2.1 Saudi Arabia
15.2.2 South Africa
15.2.3 UAE
15.2.4 Rest of Middle East & Africa (MEA)
15.3 Basis Point Share (BPS) Analysis by Country
15.4 Absolute $ Opportunity Assessment by Country
15.5 Market Attractiveness Analysis by Country
15.6 Middle East & Africa (MEA) Macular Degeneration (AMD) and Other Retinal Diseases Market Size Forecast By Disease Type
15.6.1 Wet AMD
15.6.2 Dry AMD
15.6.3 Diabetic Retinopathy
15.6.4 Retinal Vein Occlusion
15.6.5 Diabetic Macular Edema
15.6.6 Others
15.7 Basis Point Share (BPS) Analysis By Disease Type
15.8 Absolute $ Opportunity Assessment By Disease Type
15.9 Market Attractiveness Analysis By Disease Type
15.10 Middle East & Africa (MEA) Macular Degeneration (AMD) and Other Retinal Diseases Market Size Forecast By Treatment Type
15.10.1 Surgical Treatments
15.10.2 Intraocular Implants
15.10.3 Pharmacological Treatments
15.11 Basis Point Share (BPS) Analysis By Treatment Type
15.12 Absolute $ Opportunity Assessment By Treatment Type
15.13 Market Attractiveness Analysis By Treatment Type
15.14 Middle East & Africa (MEA) Macular Degeneration (AMD) and Other Retinal Diseases Market Size Forecast By Drug Class
15.14.1 Anti-VEGF Agents
15.14.2 Retinoids
15.14.3 Corticosteroids
15.14.4 Gene Therapy
15.15 Basis Point Share (BPS) Analysis By Drug Class
15.16 Absolute $ Opportunity Assessment By Drug Class
15.17 Market Attractiveness Analysis By Drug Class
15.18 Middle East & Africa (MEA) Macular Degeneration (AMD) and Other Retinal Diseases Market Size Forecast By End-user
15.18.1 Hospitals
15.18.2 Specialty Clinics
15.18.3 Ambulatory Surgical Centers
15.18.4 Others
15.19 Basis Point Share (BPS) Analysis By End-user
15.20 Absolute $ Opportunity Assessment By End-user
15.21 Market Attractiveness Analysis By End-user
Chapter 16 Competition Landscape
16.1 Macular Degeneration (AMD) and Other Retinal Diseases Market: Competitive Dashboard
16.2 Global Macular Degeneration (AMD) and Other Retinal Diseases Market: Market Share Analysis, 2023
16.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
16.3.1 Regeneron Pharmaceuticals Inc.
16.3.2 F. Hoffmann-La Roche Ltd
16.3.3 Novartis AG
16.3.4 Bayer AG
16.3.5 Pfizer Inc.
16.3.6 Bausch Health Companies Inc.
16.3.7 Apellis Pharmaceuticals,
16.3.8 Santen Pharmaceutical Co., Ltd.
16.3.9 Adverum Biotechnologies, Inc.
16.3.10 Allergan (AbbVie Inc.)
Methodology
Related Reports
Some other reports from this category!
Our Clients
